Breakout Session: Strategies for Engaging in Emerging Markets

3:00 PM - 4:00 PM

Following panel 3, in this breakout session panelists will discuss dual-market opportunities and viable commercialization strategies for partnering with emerging market manufacturers. High-level officials from emerging markets will provide practical guidance on navigating international regulatory requirements, relationships with international institutions, and the challenges of investing in emerging market companies.


  • Moderator: David Campbell, Principal, IMS Health
  • Minister Lino Barañao, Minister of Science, Technology and Innovative Production, Government of Argentina
  • Maharaj K. Bhan, Secretary, Department of Biotechnology, Government of India
  • G. Steven Burrill, CEO, Burrill & Company
  • Bongi Gumede, Senior General Manager, Technology Innovation and Marketing, Technology Innovation Agency, South Africa
  • Julio Ramundo, Managing Director, Venture Capital, Environmental and Capital Markets Division, Brazilian Development Bank (BNDES)

Who's Who


Baranao Minister Lino Barañao - Lino Barañao serves as the Minister of Science, Technology and Innovation of Argentina, an office created during the incumbent administration of Ms. Cristina Fernandez de Kirchner in 2007. Previously, Dr. Barañao acted as Chairman of the Board of Directors of the National Agency for the Promotion of Science, Technology and Innovation (ANPCyT).

Dr. Barañao is a trained scientist, and received his PhD in Chemical Sciences from the University of Buenos Aires, after which he spent time in Germany and the United States, where he held postdoctoral positions. He was appointed a fellowship at the National Research Council of Argentina (CONICET) and worked at the Institute of Experimental Biology and Medicine as Director of the Laboratory of Biotechnology for Animal Reproduction.

Dr. Barañao has received many awards for his research in animal technology and for his role as head of the ANPCyT and in the development of science in Argentina. His opinion columns have been published in a variety of major publications, and have focused on his leadership in shaping the path of Argentina as it becomes a leading global actor in the world of science and technology.
  Maharaj K. Bhan - Maharaj K. Bhan serves as the Secretary of the Ministry of Science & Technology, Department of Biotechnology of India. He is recipient of numerous awards: "Shanti Swarup Bhatnagar Award", 1990, for medical sciences, the highest Scientific Award below 45 years of age in Indian Sciences, National Ranbaxy Award, 1990, for Medical Sciences, Achar Gold Medal of the Indian Academy of Pediatrics, 1984, for the best original research, S.S. Mishra Award of the National Academy of Medical Sciences, 1986, for the best unpublished research, Biotech Product and Process Development and Commercialization Award, 2003 and Pollins Foundation Research Award for US 100,000 (Year 2003).

Dr. Bhan is involved with policy formulation role as: Chairman, WHO Task Force on child health research, Member, Board of Directors, International Vaccine Institute, Korea, Chairman, National Task Force on micronutrient policy, Member, Technical Advisory Group, World Health Organization, Member, NIH Task Force on Rotavirus Vaccines, Chairman, Maternal and Child Health Research, Indian Council of Medical Research, Chairman, Scientific Advisory Committee, National Institute of Nutrition, India, Member of the Jury for nearly all major national science awards in India such as Shanti Swarup Bhatnagar Award, Birla Science Award and Ranbaxy National Award, Member, Science
and Engineering Research Council, Department of Science and Technology, India, Member, Medical Biotechnology Board, Department of Biotechnology, Member, Technical Advisory Group, Child and Adolescent Health Division, World Health Organization, Geneva, Chairman, National Adaptation Committee, Integrated Management of Child Health, India, Member, Scientific Advisory Committee, Indian Council of Medical Research, Advisor to the Drug Regulatory Authority of India, Member, Scientific Advisory Committee, National Institute of Enteric Diseases and Cholera, India, Member, Program Advisory Committee on Medical Biology, Department of Science and Technology, India, Member, Immunization Advisory Board, Government of India. Member, Scientific Advisory Committee, Tuberculosis Research Centre, India, Member, Scientific Advisory Committee, National Institute of Epidemiology, India, Chairman, Committee for Preparation of Strategy for Promotion of neonatal health in South East Asia, SEARO.

Dr. Bhan holds the degrees of MBBS, MD Pediatrics, DSc (Honorary), and is a Fellow, Indian National Science Academy (FNA), Fellow, Academy of Sciences (FASc) and Fellow, Academy of Medical Sciences (FAMS).
Campbell David Campbell - David Campbell is a Senior Principal in Strategy and Portfolio Analysis for IMS Health. Based in the London office, he also serves as Global Leader of IMS's Emerging Markets Platform. He has over 10 years of extensive experience in the pharmaceutical and consulting industry in the US and Europe.

Prior to joining IMS, David was a Consulting Partner at Catenion Strategies, a boutique strategy consulting firm based in Berlin. At Catenion he led numerous engagements including a post merger development portfolio review for a major pharmaceutical organization, helping a new entrant into the oncology market to define the late stage development programme for a key brand that has now become a major player in the oncology space, and a number of corporate strategy initiatives.

David graduated from Strathclyde University with a degree in Immunology and Pharmacology in 1991 and from there studied for the degree of PhD at Glasgow University where his thesis was on the topic of genetics of colorectal cancer. Having graduated from Glasgow he then spent five years at the University of Leeds where he led a genetic research group interested in defining the genetic basis of a number of disorders such as Asthma, Developmental Disorders and Anorexia Nervosa.

From Leeds, David went to SmithKline Beecham where he was a Group Leader in Genetic Technologies before taking on the role of Director of Molecular Genetics Europe in the combined GSK organization. Towards the end of his tenure at GSK he was seconded into Portfolio Management where he led a team of individuals responsible for reviewing and rationalizing the Genetics Research Portfolio.

David then left GSK in 2004 and became CSO for a small VC funded company called Etiologics. He was part of the senior management team who led the purchase of Bayer's preclinical respiratory capability before helping Etiologics initiate a reverse take-over of Argenta Discovery.

Having left Etiologics at the beginning of 2005, David then spent 12 months working as an external consultant with AstraZeneca helping them define their Discovery Medicine strategy for oncology.
Burrill G. Steven Burrill -  G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Chairman of the Board of Abunda Nutrition, Inc., and is a member of the Boards of Directors of Catalyst Biosciences, Depomed (NASDAQ: DEPO), NewBridge, Proventys, Targacept (NASDAQ: TRGT) and XDx. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/ manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as a biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50), as well as being honored at the American Liver Foundation’s Annual “Salute to Excellence” Gala, which honors the best and the brightest from the Bay Area’s medical, biotech and bio-pharmaceutical industries. In 2008 he received the BayBio Pantheon 2008 DiNA lifetime achievement award for his worldwide biotech leadership.

In addition to his work with leading life science companies, Mr. Burrill is a founder and currently serves as Chairman of the Board of the Foundation for the National Medals of Science and Technology. Additionally, he serves as Chairman of the San Francisco Mayor’s Biotech Advisory Committee (MAYBAC). Mr. Burrill also chaired the National Research Council study on linkages in biotechnology between Japan and the United States. He was also involved with the US-Japan Science and Technology Agreement Study of Technology Transfer Mechanisms between the US and Japan. Other not-for-profit activities include serving on the Boards of Directors of the Bay Area Science Infrastructure Consortium, BayBio (Emeritus), California Healthcare Institute (Emeritus), The Exploratorium (Emeritus), The Kellogg Center for Biotechnology, the MIT Center for Biomedical Innovation, and the National Health Museum (Vice Chairman), World Council for Ethical Standards (Chairman), Vilas County Economic Development Group (Chairman), BIO Ventures for Global Health (BVGH), University of Wisconsin Extension, Scientific American Board of Advisors. He also serves on the editorial board of the Journal of Commercial Biotechnology and is on the advisory boards of the Center for Policy on Emerging Technologies (C-PET), as well as BioAg Gateway, City of Madison. He is an advisor to University of Illinois Institute for Genomic Biology, University of Wisconsin—College of Agriculture and Life Sciences, University of Minnesota College of Biological Sciences, and Duke University, and is an adjunct professor at University of California, San Francisco.

Bongi Gumede - Dr. Bongi Gumede is the Senior General Manager for Marketing and Technology Innovation in the Technology Innovation Agency of South Africa. The Technology Innovation Agency (TIA) was established by the South African government to stimulate and intensify technological innovation in order to improve economic growth and the quality of life of all South Africans by developing and exploiting technological innovations. The Agency is set up as a public entity with the aim to enhance the country’s capacity to translate a greater proportion of local research and development into commercial technology products and services.

He is responsible to oversee and drive TIA’s Business Development and Marketing Services to relevant stakeholders to support the Regional Technology Innovation strategies. The responsibilities include management of the implementation of the Regional Technology Innovation strategies and expand TIA’s footprints across all the Provinces of South Africa.

Previously he was the Executive Health Portfolio Manager for Biotechnology Partnerships and Development (BioPAD). His main tasks included developing and managing a balanced strategy for Human and Animal Health Portfolio for BioPAD. He was heavily involved with raising global funds especially for research and development in animal and human disease areas relevant to South Africa. He also managed the establishment of a Pre-clinical drug development platform for South Africa, an initiative of the South African government through Department of Science and Technology. He was also appointed Competency Area Manager for Drug and Therapeutic Discovery within CSIR Biosciences, to manage and oversee the drug discovery activities contained in the Bio-prospecting, Aptamer, Structural Biology, Systems Biology, Discovery Chemistry and Analytical Chemistry research groups within CSIR Biosciences. The main objective of this position was to be able to raise local and global funds for R&D activities in HIV, Malaria and Tuberculosis. 

Dr. Gumede has 11 years international experience in the research and development environment and the private sector. Dr. Gumede developed strategic partnerships with numerous key stakeholders and this has made him to be very conversant with national systems of innovation, particularly in Africa. Dr Gumede holds a Doctor of Philosophy degree in Pharmacology obtained from University of Cape Town, South Africa. His achievements include the award of the prestigious John Sainsbury/Linbury Trust Doctoral Fellowship to study part of his PhD at Oxford University, UK. He has attended Executive Development Programme at University of Stellenbosch and has published in reputable journals and presented at international conferences.